Medical News

RSS

The “Pink Star” fundraising campaign raises $1M for the National Breast Cancer Foundation

CKE Restaurants, Inc. today announced it has reached its goal of raising $1 million for breast cancer programs and awareness through its “Pink Star” fundraising campaign. During the three-week, in-store fundraiser that began in April, guests at Carl’s Jr.® and Hardee’s® restaurants across the United States donated to the campaign in support of the National Breast Cancer Foundation (NBCF).

21 Sep 2009

Mutual filtering model to be used for a new Internet matchmaking site

Robert M. Gordon, Ph.D., a psychologist-researcher and psychoanalyst, developed a comprehensive model of love relations that he will be using on the new Internet matchmaking site, RewardingLove.com (TM) http://www.RewardingLove.com).

21 Sep 2009

QualityMetric announces new tool to measure pain accurately

According to the National Centers for Health Statistics, 76.2 million Americans report problems with chronic pain; more than diabetes, heart disease, and cancer combined. The same report notes that the annual cost of chronic pain in the United States, including healthcare expenses, lost income, and productivity, is estimated to be $100 billion.

21 Sep 2009

Perrigo purchases KV Pharmaceutical's ANDA for clindamycin phosphate and benzoyl peroxide gel

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has purchased the ANDA for clindamycin phosphate (1%) and benzoyl peroxide (5%) gel from KV Pharmaceutical for $14 million in cash at closing and a $2 million milestone payment upon the completion of a successful technical transfer. This product is the AB-rated equivalent to Stiefel Laboratories' (a subsidiary of Glaxo SmithKline) Duac(R) gel, indicated for the topical treatment of inflammatory acne vulgaris.

21 Sep 2009

GE Capital deploys $1 billion in the U.S. healthcare market for the first six months of 2009

GE Capital’s Healthcare Financial Services business ended the first six months of 2009 as one of the most active capital providers in the U.S. healthcare market, deploying approximately $1 billion for more than 45 transactions. Loans were used to refinance existing debt, support working capital needs and fund growth initiatives.

21 Sep 2009

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.

21 Sep 2009

Recession is contributing to acute physical pain for Americans: Survey

A new survey from the American Pain Foundation says economic pain from the recession is contributing to acute, or short-term, physical pain for Americans. According to the survey, released today during National Pain Awareness Month, 68 percent of people who experienced acute back pain or other minor muscle strains and sprains in the past year said that the recession caused, increased or affected their pain, often because of greater stress and working harder at home and on the job.

21 Sep 2009

Celsion recommended to continue patient enrollment in its ThermoDox Phase III liver cancer trial

Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board (“DSMB”) has reviewed the safety data from the first group of patients enrolled in its pivotal ThermoDox® Phase III clinical trial for primary liver cancer (“HEAT study”) and has recommended that Celsion continue to enroll patients in the trial.

21 Sep 2009

Phytel releases new version of its web-based Proactive Patient Outreach Solution

Phytel, the leading provider of information technology that empowers physician-led health improvement, today announced that version 5 of its web-based Proactive Patient Outreach Solution has been released and fully deployed to all of its customers.

21 Sep 2009

Cyntellect releases new cell cytometry system

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, today unveiled its Celigo™ adherent cell cytometry system, the Company’s new platform for non-invasive in situ live cell imaging.

21 Sep 2009

Phase II trial of Impax Pharmaceuticals' Parkinson’s disease drug candidate successful

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today reported the positive results from a recently completed Phase II trial of its late-stage Parkinson’s Disease drug candidate IPX066

21 Sep 2009

Primeradx raises funds for commercialization of their technology

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has closed on its $20 million Series C financing. The financing was led by CHL Medical Partners and also included significant participation by many of the Company’s existing investors; Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Company and the Invus Group.

21 Sep 2009

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.

21 Sep 2009

Maxygen completes joint venture transaction with Astellas Pharma

Maxygen, Inc. (Nasdaq:MAXY) today announced the consummation of the transactions contemplated by the previously announced joint venture agreement between Maxygen and Astellas Pharma Inc. Under the joint venture transaction, which closed on September 18, 2009, the parties established a newly-formed joint venture, Perseid Therapeutics LLC, to focus on the discovery, research and development of multiple protein pharmaceutical programs.

21 Sep 2009

Two new products released by Simbionix USA Corporation

Simbionix USA Corporation, the world's leading developer of medical simulation systems, just released two new products: a new Laparoscopic Essential Tasks Module for its LAP Mentor(TM) and a breakthrough technology for patient-specific simulation based on actual patient data - the PROcedure Rehearsal Studio(TM).

21 Sep 2009

U.S. Department of Health & Human Services requests BioCryst for proposal for peramivir supply

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received a request for proposal (RFP) from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA).

21 Sep 2009

Swedish researcher to receive Fernström Foundation's Nordic Prize

Internationally renowned Swedish researcher Professor Jan-Åke Gustafsson, from KI and the University of Houston, is this year's recipient of the Fernström Foundation's Nordic Prize. The prize, which is worth SEK 1 million, is one of Scandinavia's most prestigious medical prizes.

21 Sep 2009

HHS awards $77.2 million contract to BioCryst to complete Phase 3 development of peramivir

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has been awarded a $77.2 million contract modification by the U.S. Department of Health & Human Services (HHS) to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous (i.v.) peramivir, for the treatment of complicated influenza.

21 Sep 2009

Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany.

21 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

Medical News

The “Pink Star” fundraising campaign raises $1M for the National Breast Cancer Foundation

Mutual filtering model to be used for a new Internet matchmaking site

QualityMetric announces new tool to measure pain accurately

Perrigo purchases KV Pharmaceutical's ANDA for clindamycin phosphate and benzoyl peroxide gel

GE Capital deploys $1 billion in the U.S. healthcare market for the first six months of 2009

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

Recession is contributing to acute physical pain for Americans: Survey

Celsion recommended to continue patient enrollment in its ThermoDox Phase III liver cancer trial

Phytel releases new version of its web-based Proactive Patient Outreach Solution

Cyntellect releases new cell cytometry system

Phase II trial of Impax Pharmaceuticals' Parkinson’s disease drug candidate successful

Primeradx raises funds for commercialization of their technology

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

Maxygen completes joint venture transaction with Astellas Pharma

Two new products released by Simbionix USA Corporation

U.S. Department of Health & Human Services requests BioCryst for proposal for peramivir supply

Swedish researcher to receive Fernström Foundation's Nordic Prize

HHS awards $77.2 million contract to BioCryst to complete Phase 3 development of peramivir

Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News